Search results for "Fungal infections"

showing 10 items of 31 documents

Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell tra…

2019

Abstract Background There is growing evidence that community‐acquired respiratory virus (CARV) increases the risk of pulmonary invasive fungal disease (IFD) in the allogeneic hematopoietic stem cell transplantation (allo‐HSCT) setting. To date, there is a lack of knowledge regarding the risk factors (RFs), as well as the most critical period for subsequent onset of IFD after CARV infections in allo‐HSCT recipients. Methods In this prospective longitudinal observational CARV survey, we analyzed the effect of CARV on subsequent IFD development in 287 adult allo‐HSCT recipients diagnosed with 597 CARV episodes from December 2013 to December 2018. Multiplex PCR panel assays were used to test CA…

AdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentHematopoietic stem cell transplantation030230 surgeryYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsRespiratory virus infectionSurveys and QuestionnairesInternal medicinemedicineHumansTransplantation HomologousLongitudinal StudiesProspective Studiesallogeneic hematopoietic stem cell transplantationRespiratory systemRespiratory Tract InfectionsAgedcommunity-acquired respiratory virusTransplantationcommunity‐acquired respiratory virusbusiness.industryIncidenceIncidence (epidemiology)Hematopoietic Stem Cell TransplantationOriginal Articlesinvasive pulmonary fungal diseaseOdds ratioMiddle AgedTransplant Recipientsinvasive AspergillosisConfidence intervalCommunity-Acquired InfectionsInfectious DiseasesInvasive fungal diseaseRespiratory virusFemaleOriginal Article030211 gastroenterology & hepatologybusinessInvasive Fungal Infectionsimmunodeficiency score indexTransplant Infectious Disease
researchProduct

Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients

2020

Abstract Diagnosis, treatment, and management of invasive mould infections (IMI) are challenged by several risk factors, including local epidemiological characteristics, the emergence of fungal resistance and the innate resistance of emerging pathogens, the use of new immunosuppressants, as well as off-target effects of new oncological drugs. The presence of specific host genetic variants and the patient's immune system status may also influence the establishment of an IMI and the outcome of its therapy. Immunological components can thus be expected to play a pivotal role not only in the risk assessment and diagnosis, but also in the treatment of IMI. Cytokines could improve the reliability…

AdultMalemedicine.medical_specialtyTreatment responseAntifungal Agentshemato-oncological malignanciesAspergillosismucormycosis03 medical and health sciencesImmunocompromised HostImmune systemSDG 3 - Good Health and Well-beingInternal medicineNeoplasmsEpidemiologyimmunological statusmedicineHumansIntensive care medicine030304 developmental biologyAgedAged 80 and over0303 health sciencesHematology030306 microbiologybusiness.industryinvasive pulmonary aspergillosishematologyMucormycosisCancerReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseaseInfectious Diseaseshemato-oncological malignancies; hematology; immunological status; invasive pulmonary aspergillosis; mucormycosisAcademicSubjects/SCI00960FemaleOriginal ArticleRisk assessmentbusinessAcademicSubjects/MED00010Invasive Fungal Infections
researchProduct

Antibody Complementarity-Determining Regions (CDRs) Can Display Differential Antimicrobial, Antiviral and Antitumor Activities

2008

9 p. Background: Complementarity-determining regions (CDRs) are immunoglobulin (Ig) hypervariable domains that determine specific antibody (Ab) binding. We have shown that synthetic CDR-related peptides and many decapeptides spanning the variable region of a recombinant yeast killer toxin-like antiidiotypic Ab are candidacidal in vitro. An alanine-substituted decapeptide from the variable region of this Ab displayed increased cytotoxicity in vitro and/or therapeutic effects in vivo against various bacteria, fungi, protozoa and viruses. The possibility that isolated CDRs, represented by short synthetic peptides, may display antimicrobial, antiviral and antitumor activities irrespective of Ab…

Antifungal AgentsBIOCHEMISTRY AND MOLECULAR BIOLOGYMolecular Sequence DataImmunologylcsh:MedicineAntineoplastic AgentsMicrobial Sensitivity TestsComplementarity determining regionBiologyAntiviral AgentsOncology/Skin CancersAntibodiesMiceMicrobiology/Applied MicrobiologyAntigenBiochemistry/Protein ChemistryInfectious Diseases/Fungal InfectionsIn vivoCell Line TumorCandida albicansInfectious Diseases/Viral InfectionsAnimalsHumansAmino Acid Sequencelcsh:SciencePeptide sequenceMultidisciplinaryMEDICINElcsh:RAntimicrobialComplementarity Determining RegionsVirologyIn vitroOncologyBiochemistryViral replicationAGRICULTURAL AND BIOLOGICAL SCIENCESVirology/Immunodeficiency VirusesHIV-1biology.proteinlcsh:QAntibodyResearch ArticlePLoS ONE
researchProduct

Choosing the Right Antifungal Agent in ICU Patients

2019

Fungi are responsible for around 20% of microbiologically documented infections in intensive care units (ICU). In the last decade, the incidence of invasive fungal infections (IFI), including candidemia, has increased steadily because of increased numbers of both immunocompromised and ICU patients. To improve the outcomes of patients with IFI, intensivists need to be aware of the inherent challenges. This narrative review summarizes the features of routinely used treatments directed against IFI in non-neutropenic ICU patients, which include three classes of antifungals: polyenes, azoles, and echinocandins. ICU patients' pathophysiological changes are responsible for deep changes in the phar…

AzolesAntifungal AgentsReviewKidney Function TestsInvasive aspergillosiEchinocandins0302 clinical medicineLiver Function Tests[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesMedicineDrug InteractionsPharmacology (medical)030212 general & internal medicineComputingMilieux_MISCELLANEOUSmedia_common[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases0303 health sciencesIncidenceIncidence (epidemiology)CandidiasisGeneral MedicineSerum concentrationIntensive care patients3. Good healthIntensive Care UnitsPractice Guidelines as Topic[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCandidiasiNarrative reviewDrug MonitoringInvasive fungi infectionAntifungalDrugmedicine.medical_specialtyIcu patientsmedicine.drug_classmedia_common.quotation_subjectPharmacokineticPolyenesImmunocompromised Host03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIntensive careHumansPharmacokinetics[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyIntensive care medicineIntensive care patient030306 microbiologybusiness.industry[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyInvasive aspergillosisLiver functionbusinessPractical guidelinesInvasive Fungal InfectionsAdvances in Therapy
researchProduct

Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hem…

2014

Background Antifungal prophylaxis is a promising strategy for reducing invasive fungal infections (IFIs) in allogeneic hematopoietic cell transplant (alloHCT) recipients, but the optimum prophylactic agent is unknown. We used mixed treatment comparison (MTC) meta-analysis to compare clinical trials examining the use of oral antifungals for prophylaxis in alloHCT recipients, with the goal of informing medical decision-making. Methods Randomized controlled trials (RCTs) of fluconazole, itraconazole, posaconazole, and voriconazole for primary antifungal prophylaxis were identified through a systematic literature review. Outcomes of interest (incidence of IFI/invasive aspergillosis/invasive can…

Azolesmedicine.medical_specialtyPosaconazolePathologyAntifungal AgentsItraconazoleAspergillosisAntifungalInterquartile rangeInvasive fungal infectionsMixed treatment comparisonInternal medicinemedicineHumansRandomized Controlled Trials as TopicVoriconazolebusiness.industryHematopoietic Stem Cell TransplantationBayes Theoremmedicine.diseaseTransplant RecipientsClinical trialInfectious DiseasesTolerabilityMycosesAlloHCTbusinessFluconazolemedicine.drugResearch ArticleBMC Infectious Diseases
researchProduct

Management of infections in cirrhotic patients: Report of a Consensus Conference

2014

a b s t r a c t The statements produced by the consensus conference on infection in end-stage liver disease promoted by the Italian Association for the Study of the Liver, are here reported. The topics of epidemiology, risk factors, diagnosis, prophylaxis, and treatment of infections in patient with compensated and decompensated liver cirrhosis were reviewed by a scientific board of experts who proposed 26 statements that were graded according to level of evidence and strength of recommen- dation, and approved by an independent jury. Each topic was explored focusing on the more relevant clinical questions. By systematic literature search of available evidence, comparison and discussion of e…

Fungal infectionLiver Cirrhosismedicine.medical_specialtyAntifungal Agentsmedia_common.quotation_subjectInfectionsGastroenterologyBacterial infection; Cirrhosis; Fungal infections; Infections; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Evidence-Based Medicine; Humans; Liver Cirrhosis; Mycoses; Hepatology; GastroenterologyLiver diseaseFungal infectionsJuryInternal medicineEpidemiologymedicineHumansIn patientGrading (education)Bacterial infection; Cirrhosis; Fungal infections; Infectionsmedia_commonCirrhosiEvidence-Based MedicineHepatologybusiness.industryConsensus conferenceGastroenterologyEvidence-based medicineBacterial Infectionsmedicine.diseaseAnti-Bacterial AgentsMycosesCirrhosisFamily medicineBacterial infectionbusinessInfectionSystematic search
researchProduct

Monitoring neonatal fungal infection with metabolomics

2014

Abstract The objective of our study was to evaluate the capability of the metabolomics approach to identify the variations of urine metabolites over time related to the neonatal fungal septic condition. The study population included a clinical case of a preterm neonate with invasive fungal infection and 13 healthy preterm controls. This study showed a unique urine metabolic profile of the patient affected by fungal sepsis compared to urine of controls and it was also possible to evaluate the efficacy of therapy in improving patient health.

Fungal infectionmedicine.medical_specialtyUrineInfant Newborn DiseasessepsisSepsisSettore MED/38 - Pediatria Generale E SpecialisticaMetabolomicsIntensive Care Units NeonatalmedicineHumansMetabolomicsIntensive care medicinePrincipal Component AnalysisPatient affectedbusiness.industryInfant NewbornObstetrics and Gynecologymedicine.diseaseItalyMycosesfungal infectionsPediatrics Perinatology and Child HealthMetabolomePopulation studyMetabolomic; fungal infections; PrematurityFungal sepsisClinical caseneonatePrematuritybusinessBiomarkersMetabolic profilemetabolomicThe Journal of Maternal-Fetal & Neonatal Medicine
researchProduct

Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference

2014

SummaryThe burden of infectious diseases both before and after liver transplantation is clearly attributable to the dysfunction of defensive mechanisms of the host, both as a result of cirrhosis, as well as the use of immunosuppressive agents.The present document represents the recommendations of an expert panel commended by the Italian Association for the Study of the Liver (AISF), on the prevention and management of infectious complications excluding hepatitis B, D, C, and HIV in the setting of liver transplantation.Due to a decreased response to vaccinations in cirrhosis as well as within the first six months after transplantation, the best timing for immunization is likely before transp…

Liver Cirrhosismedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationInfectionsInvasive fungal infectionPostoperative ComplicationsBacterial infectionsInvasive fungal infectionsTransplantation ImmunologyLower respiratory tract infectionHumansMedicineSmallpoxVoluntary Health AgenciesIntensive care medicineImmunosuppression TherapyViral infectionsInfection ControlCirrhosiLiver transplantationAttenuated vaccineHepatologybusiness.industryVaccinationHepatitis Bmedicine.diseaseVaccinationTransplantationBacterial infections; Cirrhosis; Invasive fungal infections; Liver transplantation; Viral infections; Humans; Immunosuppression; Infection; Infection Control; Italy; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Transplantation Immunology; Vaccination; Voluntary Health Agencies; HepatologyCirrhosisItalyViral infectionBacterial infections; Cirrhosis; Invasive fungal infections; Liver transplantation; Viral infectionsAISFImmunologyBacterial infectionInfectionbusinessImmunosuppression
researchProduct

Associations of Antifungal Treatments With Prevention of Fungal Infection in Critically Ill Patients Without Neutropenia

2017

BACKGROUND: Invasive fungal infections are important causes of morbidity and mortality among critically ill patients. Early institution of antifungal therapy is pivotal for mortality reduction. Starting a targeted antifungal therapy after culture positivity and fungi identification requires a long time. Therefore, alternative strategies (globally defined as 'untargeted antifungal treatments') for antifungal therapy institution in patients without proven microbiological evidence of fungal infections have been discussed by international guidelines. This review was originally published in 2006 and updated in 2016. This updated review provides additional evidence for the clinician dealing with …

Medicine General & Introductory Medical Sciences0301 basic medicineAntifungalmedicine.medical_specialtyAntifungal AgentsNeutropeniaSystemic mycosismedicine.drug_classCritical Illness030106 microbiologyMycoseNeutropeniaPlacebo03 medical and health sciences0302 clinical medicinemedicineAntifungal AgentHumansInvasive Fungal InfectionMED/41 - ANESTESIOLOGIAIntensive care medicinebusiness.industryCritically illMedicine (all)030208 emergency & critical care medicineGeneral Medicinemedicine.diseaseMycosesClinical questionCritical illnessCritical IllnebusinessInvasive Fungal InfectionsHumanJAMA
researchProduct

Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients: An upda…

2022

Microbiology (medical)AdultInvasive Pulmonary AspergillosisIntensive Care UnitsAspergillusInfectious DiseasesCOVID-19 TestingCritical IllnessAspergillosisCOVID-19HumansSettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICAInvasive Fungal InfectionsThe Journal of infection
researchProduct